Thus, the plasma ACTH, plasma cortisol, and serum levels of IL-2 and IFN-γ will be examined in this study to determine whether JTN treatment affects the immune and HPA functions of CFS patients. The gene discussed is IL2; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.